Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $125.00 by Analysts at JMP Securities

Blueprint Medicines (NASDAQ:BPMC) had its target price boosted by JMP Securities from $114.00 to $125.00 in a research report released on Friday morning, Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

BPMC has been the topic of several other research reports. Stifel Nicolaus boosted their price target on shares of Blueprint Medicines from $120.00 to $130.00 and gave the stock a buy rating in a research report on Friday, April 26th. Wedbush restated an outperform rating and issued a $110.00 price target on shares of Blueprint Medicines in a research report on Friday, April 26th. HC Wainwright boosted their price target on shares of Blueprint Medicines from $125.00 to $135.00 and gave the stock a buy rating in a research report on Friday. Barclays boosted their price target on shares of Blueprint Medicines from $70.00 to $75.00 and gave the stock an equal weight rating in a research report on Friday. Finally, Citigroup lifted their price objective on shares of Blueprint Medicines from $54.00 to $65.00 and gave the stock a sell rating in a research note on Friday, February 16th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $100.31.

Blueprint Medicines Trading Down 0.9 %

Blueprint Medicines stock opened at $106.25 on Friday. The stock has a market cap of $6.50 billion, a P/E ratio of -22.14 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. Blueprint Medicines has a 1 year low of $43.89 and a 1 year high of $110.93. The firm’s 50 day moving average price is $91.77 and its 200-day moving average price is $80.95.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $71.96 million for the quarter, compared to analysts’ expectations of $67.34 million. During the same quarter last year, the business posted ($2.65) earnings per share. The company’s revenue for the quarter was up 85.5% compared to the same quarter last year. On average, equities analysts predict that Blueprint Medicines will post -5.38 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Christopher K. Murray sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. Following the completion of the sale, the insider now directly owns 24,495 shares of the company’s stock, valued at $2,449,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Christopher K. Murray sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total value of $500,000.00. Following the completion of the sale, the insider now directly owns 24,495 shares of the company’s stock, valued at $2,449,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Tracey L. Mccain sold 5,194 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $471,043.86. Following the completion of the sale, the executive vice president now directly owns 60,498 shares of the company’s stock, valued at $5,486,563.62. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 104,123 shares of company stock valued at $9,554,679. 3.88% of the stock is currently owned by company insiders.

Institutional Trading of Blueprint Medicines

A number of hedge funds have recently added to or reduced their stakes in BPMC. Bank of New York Mellon Corp lifted its stake in Blueprint Medicines by 1.6% in the third quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock worth $13,396,000 after acquiring an additional 4,127 shares during the period. Brown Advisory Inc. raised its holdings in Blueprint Medicines by 0.9% in the third quarter. Brown Advisory Inc. now owns 641,039 shares of the biotechnology company’s stock worth $32,193,000 after purchasing an additional 5,843 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Blueprint Medicines by 9.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,055 shares of the biotechnology company’s stock worth $605,000 after purchasing an additional 1,052 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Blueprint Medicines by 4.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,269 shares of the biotechnology company’s stock worth $1,872,000 after purchasing an additional 1,417 shares in the last quarter. Finally, Emerald Advisers LLC raised its holdings in Blueprint Medicines by 22.4% in the third quarter. Emerald Advisers LLC now owns 607,037 shares of the biotechnology company’s stock worth $30,485,000 after purchasing an additional 110,984 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.